WEBULL

Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story?

Simply Wall St · 2d ago
  • Alnylam Pharmaceuticals recently presented at the Alzheimer’s Association International Conference 2026 in London, sharing Phase 1 and Phase 2 updates on its RNAi candidate mivelsiran for early-onset and Down syndrome-associated Alzheimer’s disease, as well as progress on ALN-5288 and other neuroscience programs with Regeneron.
  • The company reported long-term biomarker reductions and a favorable safety profile for mivelsiran, while fully enrolling its Phase 2 cerebral amyloid angiopathy study, underscoring a broader push to apply RNA interference to hard-to-treat neurodegenerative conditions.
  • We’ll now examine how mivelsiran’s biomarker and safety data at AAIC 2026 could influence Alnylam’s longer-term investment narrative in neuroscience.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Alnylam Pharmaceuticals Investment Narrative Recap

To own Alnylam, you need to believe that its RNAi platform can keep expanding beyond the TTR franchise while maintaining disciplined spending and access to payers. The AAIC 2026 mivelsiran update looks additive to the longer term diversification story but does not change the near term focus on AMVUTTRA pricing dynamics and margin pressure as the key catalyst and risk in the stock today.

Within this AAIC news, the completion of enrollment in the Phase 2 cAPPricorn-1 trial for cerebral amyloid angiopathy stands out, because it moves a non TTR, high unmet need indication to a clear data milestone in 2028. That timing now sits alongside payer and pricing developments for AMVUTTRA as important waypoints investors are watching as the company invests heavily in neuroscience.

However, against this encouraging neuroscience progress, investors should still weigh the risk that concentrated dependence on AMVUTTRA and TTR therapies could...

Read the full narrative on Alnylam Pharmaceuticals (it's free!)

Alnylam Pharmaceuticals' narrative projects $9.0 billion revenue and $2.0 billion earnings by 2029. This requires 28.3% yearly revenue growth and about a $1.5 billion earnings increase from $538.0 million.

Uncover how Alnylam Pharmaceuticals' forecasts yield a $434.72 fair value, a 63% upside to its current price.

Exploring Other Perspectives

ALNY 1-Year Stock Price Chart
ALNY 1-Year Stock Price Chart

Some of the lowest ranked analysts were already cautious before AAIC, assuming Alnylam would reach about US$8.4 billion of revenue and US$1.2 billion of earnings by 2029, and they stress that even strong mivelsiran data may not fully offset ongoing pricing pressure and heavy reliance on TTR therapies, so it is worth comparing their more pessimistic view with the more optimistic RNAi diversification story you have just read.

Explore 4 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.